|
PI3K/AKT pathway biomarkers analysis from the phase III IPATential150 trial of ipatasertib plus abiraterone in metastatic castration-resistant prostate cancer. |
|
|
Employment - Institute of Cancer Research |
Honoraria - Amgen; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Bayer; BioExcel; Boehringer Ingelheim; Celgene; CellCentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen Oncology; Medivation; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Sanofi; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex |
Consulting or Advisory Role - Amgen; Astellas Pharma; Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; CellCentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen Oncology; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Sanofi; Sanofi Aventis GmbH; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex |
Research Funding - Amgen; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Bayer; CellCentric; Daiichi Sankyo; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi; Sanofi Aventis GmbH; Sierra Oncology; Taiho Pharmaceutical; Vertex |
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst) |
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; Cellcentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Qiagen; Sanofi; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex |
|
|
Stock and Other Ownership Interests - Leuchemix |
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Celgene; Genentech/Roche; Janssen Biotech; Lilly; Pfizer; Sanofi |
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Pfizer (Inst); Sanofi (Inst) |
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination |
|
|
Consulting or Advisory Role - Bayer Schering Pharma; Bayer Schering Pharma; Bristol-Myers Squibb; Ipsen; MSD Oncology; Pfizer; Roche/Genentech |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Exelixis/Ipsen; Ipsen; Janssen Oncology; Pfizer; Roche |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Genzyme; Immunomedics; Incyte; Medscape; Merck; MSD; Pfizer; Roche; UroToday |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck; Roche |
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Constellation Pharmaceuticals; Daiichi Sankyo; ESSA; Janssen; Merck; POINT Biopharma; Roche; Sanofi |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); ESSA (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst) |
|
|
Honoraria - Astellas Pharma (Inst); Bayer; Janssen |
Consulting or Advisory Role - AstraZeneca (Inst); Bayer; Bayer (Inst); Clovis Oncology; Daiichi Sankyo; Janssen; Janssen (Inst); MSD Oncology |
Research Funding - Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); Janssen (Inst); MSD Oncology (Inst); Pfizer (Inst); Tokai Pharmaceuticals (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Ipsen; Janssen; Roche |
|
|
Honoraria - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Merck Serono (Inst) |
Consulting or Advisory Role - Amgen |
Speakers' Bureau - Bristol-Myers Squibb; Merck; Roche/Genentech |
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Endocyte/Advanced Accelerator Applications (Inst); Genentech/Roche (Inst); Merck (Inst) |
Travel, Accommodations, Expenses - Roche/Genentech |
|
|
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Blueprint Medicines; Bristol-Myers Squibb; Celgene; Debiopharm Group; Genentech/Roche; INNATE PHARMA; IPSEN; Janssen; Lilly; MSD; Novartis; ORION; Pfizer; PharmaMar; Sanofi; Taiho Pharmaceutical |
|
|
Honoraria - AstraZeneca; Bayer; Chugai Pharma (Inst); Janssen; MSD |
Consulting or Advisory Role - AstraZeneca; Janssen; Lilly; Sanofi |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Janssen (Inst); MSD (Inst) |
|
|
No Relationships to Disclose |
|
|
|
|
|
Employment - Genentech/Roche |
Stock and Other Ownership Interests - Genentech/Roche |
|
|
Employment - Genentech/Roche |
Stock and Other Ownership Interests - Genentech/Roche |
Travel, Accommodations, Expenses - Genentech/Roche |